Aminoglycoside-induced nephrotoxicity in cystic fibrosis: A case presentation and review of the literature

American Journal of Therapeutics

Volumn 3, Issue 3, 1996, Pages 248-257

  Samaniego Picota, M D ^b   Whelton, A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

acute renal failure; aminoglycosides; CFTR; cystic fibrosis; nephrotoxicity; P glycoprotein; pharmacokinetics; renal drug clearance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; VANCOMYCIN;

ADULT; ARTICLE; CASE REPORT; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; NEPHROTOXICITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029935506     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199603000-00011     Document Type: Article

References (57)

1. Levison ME: New dosing regimens for aminoglycoside antibiotics. Ann Intern Med 1992;117:693-694.
2. Moore RD, Smith CR, Lipsky JJ, Mellits D, Lietman PS: Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984;100:352-357.
3. Melnick JZ, Baum M, Thompson JR: Aminoglycoside-induced Fanconi's Syndrome. Am J Kidney Dis 1994;23: 118-122.
4. Luft FC, Kleit SA: Renal parenchymal accumulation of aminoglycoside antibiotics in rats. J Infect Dis 1974;130: 656.
5. Conger JD, Briner VA, Schrier RW: Acute renal failure: pathogenesis, diagnosis and management. In: Renal and Electrolyte Disorders, 3rd ed. (Ed. Schrier RW), Little-Brown, Boston, 1992.
6. Colten HR: Cystic fibrosis. In: Harrison's Principles of Internal Medicine, 11th ed. (Eds. Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS), McGraw-Hill, New York, 1987, pp. 1085-1087.
7. Schwachman H: The sweat test: sodium and chloride values. J Pediatr 1981;98:576.
8. Boucher RC: Cystic fibrosis. In: Harrison's Principles of Internal Medicine, 13th ed. (Eds. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL), McGraw-Hill, New York, 1994, pp. 1194-1197.
9. Harris A, Argent BE: The cystic fibrosis gene and its product CFTR. Semin Cell Biol 1993;4:37.
10. Cheng SH: Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990;63:827.
11. Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, Maass G, Tummler B: Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmembrane-conductance regulator mRNA transcripts in human epithelia. Eur J Biochem 1992;206:137-149.
12. Arceci RJ, Croop JM, Horwitz SB, Housman DE: The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988;85:4350-4354.
13. Busche R, Tummler B, Riordan JR, Cano-Gauci DF: Preparation and utility of a radioiodinated analogue of daunomycin in the study of multidrug resistance. Molec Pharmacol 1989;35:414-121.
14. Crawford I, Maloney PC, Zeitlin PL, Guggino WB, Hyde SC, Turley H, Gatter KC, Harris A, Higgins CF: Immunocytochemical localization of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci USA 1991;88:9262-9266.
15. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738.
16. Riordan JR, Rommens JM, Kerem BS, Alon N, Rozmahel R, Grzelczak Z, Zielinski J, Lok S, Plavsic N, Chou JL, Drumm ML, Iannuzzi MC, Collins FS, Tsui L-C: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073.
17. Anderson MP, Rich DP, Gregory RJ, Smith AE, Welsh MJ: Generation of cAMP-activated chloride currents by expression of CFTR. Science 1991;251:679-682.
18. Barasch J, Kiss B, Prince A, Salman L, Gruenert D, Al-Awqati Q: Defective acidification of intracellular organelles in cystic fibrosis. Nature 1991;352:70-73.
19. Al-Awqati Q, Barasch J, Landry D: Chloride channels of intracellular organelles and their potential role in cystic fibrosis. J Exp Biol 1992;172:245-266.
20. Knowles M: Increased bioelectrical potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981;305:1489.
21. Lindsay CA, Bosso JA: Optimization of antibiotic therapy in cystic fibrosis patients: pharmacokinetic considerations. Clin Pharmacokinet 1993;24:496-506.
22. Spino M: Pharmacokinetics of drugs in cystic fibrosis. Clin Rev Allergy 1991;9(1-2):169-210.
23. di Sant' Agnese PA, Davis PB: Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature. Am J Med 1979;66:121-132.
24. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B: Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984;105:117-124.
25. Robson AM, Tateishi S, Ingelfinger JR, Strominger DB, Khlar S: Renal function in patients with cystic fibrosis. J Pediatr 1971;79:42-50.
26. Michaelsen H, Monn E, Bergan T, Churg J, Johannessen JV: Renal biopsies in cystic fibrosis. Pathol Res Pract 1984;178:261-267.
27. Boucher R, Beall R: Summary of drug needs in cystic fibrosis. Pharm Res 1989;6:525-527.
28. Sande MA, Mandell GL: In: The Pharmacological Basis of Therapeutics, (8th ed). Antimicrobial agents. (Eds., Gilman AG, Rail TW, Nies AS, Taylor P), Pergamon Press, New York, 1990, pp 1098-1116.
29. Hedman A, Adan-abdi Y, Alvan G, Strandvik B: Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. Clin Pharmacokinet 1988;15:57-65.
30. Silverblatt FJ: Autoradiographic studies of intracellular aminoglycoside deposition in the kidney. In: The Aminoglycosides: Microbiology, Clinical Use, and Toxicology (Eds. Whelton A, Neu HC), Marcel Dekker, New York, 1982, pp. 223-233.
31. Sastrasinh M, Knauss TC, Weinberg JM, Humes HD: Identification of the aminoglycoside binding site in rat renal brush border membrane. J Pharmacol Exp Ther 1982;222:350-358.
32. Verpooten GA, Giuliano RA, Pattyn VM, Scharpe SL, De Broe ME: Renal cortical uptake kinetics of gentamicin in rats with impaired renal function. Am J Kidney Dis 1986;5:304-307.
33. Wedeen RP, Batuman V, Cheeks C, Marquet E, Sobel H: Transport of gentamicin in rat proximal tubule. Lab Invest 1983;48:212.
34. Fahre J, Rudhardt M, Blanchard P, Regamey L: Persistence of sisomicin and gentamicin in renal cortex and medulla compared with other organs and serum of rats. Kidney Int 1976;10:444-449.
35. Luft FC: Comparative nephrotoxicity of aminoglycoside antibiotics in rats. J Infect Dis 1978;138:541.
36. Crampton RF, Smyth DH: The excretion of enantiomorphs of amino acids. J Physiol 1953;122:1-10.
37. Whelton A: Renal tubular transport and intrarenal aminoglycoside distribution. In: The Aminoglycosides: Microbiology, Clinical Use, and Toxicology (Eds. Whelton A, Neu HC), Marcel Dekker, New York, 1982, pp. 191-222.
38. Kildoo CW, Harralson AF, Folli HL, Kelly PC, Nussbaum E: Direct determination of tobramycin clearance in patients with mild-to-moderate cystic fibrosis. Drug Intell Clin Pharm 1987;21:639-641.
39. Bosso JA, Townsend PL, Herbst JJ, Matsen JM: Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients. Antimicrob Agents Chemother 1985;25: 579-581.
40. Munzenberger PJ, Commissaris RL, Massoud N, Hsu M-C: Variability of tobramycin pharmacokinetics in cystic fibrosis. Pediatr Infect Dis J 1987;6:739-743.
41. Smith CR, Moore RD, Lietman PS: Studies of risk factors for aminoglycoside nephrotoxicity. Am J Kidney Dis 1986;8:308-313.
42. Meyer RD: Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides. Am J Med 1986; 80(Suppl 6B):119-125.
43. Bennett WM, Parker RA, Elliot WC, Gilbert DN, Houghton DC: Sex-related differences in the susceptibility of rats to gentamicin nephrotoxicity. Medicine 1982;61:258-268.
44. Thompson JR, Simonsen R, Spindler MA, Southern PM, Cronin RE: Protective effect of KCl loading in gentamicin nephrotoxicity. Am J Kidney Dis 1990;15:583-591.
45. Fukuda Y, Eklof A-C, Malmborg A-S, Aperia A: Calcium supplementation and thyroid hormone protect against gentamicin-induced inhibition of proximal tubular Na+,K+-ATPase activity and other renal functional changes. Acta Physiol Scand 1992;145:93-98.
46. Kepczyk T, Ryan III PJ, McAllister K, Otraje J: The absence of nephrotoxicity and differential nephrotoxicity between tobramycin and gentamicin. South Med J 1990; 83:1149-1152.
47. Bock BV, Edelstein PH, Meyer RD: Prospective comparative study of efficacy and toxicity of netilmicin and amikacin. Antimicrob Agents Chemother 1980;17:217-225.
48. Brezis M, Rosen S, Epstein FH: Acute renal failure. In: The Kidney, Vol I (Eds. Brenner BM, Rector Jr FC), W.B. Saunders, Philadelphia, 1991, pp. 998-1000.
49. Swan SK, Bennett WM: Nephrotoxic acute renal failure. In: Acute Renal Failure (Eds. Lazarus JM, Brenner BM), Churchill Livingstone, New York, 1993, pp. 361-378.
50. Molitoris BA, Meyer C, Dahl R, Geerdes A: Mechanism of ischemia-enhanced aminoglycoside binding and up-take by proximal tubule cells. Am J Physiol 1993;264 (5, Pt 2):F907-F916.
51. Cadeddu JA, Whelton A: Vancomycin nephrotoxicity. Am J Ther 1994;1:1-7.
52. Appel GB, Given DB, Levine LR, Cooper GL: Vancomycin and the kidney. Am J Kidney Dis 1986;8:75.
53. Goetz MB, Sayers J: Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993;32:325-334.
54. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH: Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25:679-687.
55. Ngeleka M, Beauchamp D, Tardif D, Auclair P, Gourde P, Bergeron MG: Endotoxin increases the nephrotoxic potential of gentamicin and vancomycin plus gentamicin. J Infect Dis 1990;161:721-727.
56. Eisenberg JM, Koffer H, Glick HA, Connell ML, Loss LE, Talbot GH, Shusterman NH, Strom BL: What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987;107:900-909.
57. Moestrup SK, et al.: Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995; 96:1404.